STATE-OF-THE-ART SWISS GENETIC ENGINEERING WITH A PURIFICATION RATE OF 99.8%
1 MILLILITRE OF THE PREPARATION CONTAINS:
Recombinant human insulin-like growth factor (IGF-1) – 5 mg
Sodium acetate – 2 mg
Benzyl alcohol – 5 mg
The only difference between “Infrajet” and its American analogue is the absence of binding protein, that’s why it acts immediately (3 hours after administration) and its concentration in the blood is 2-3 times higher.
The medication was developed in a private scientific laboratory in Switzerland under conditions of medical sterility. It meets all the requirements of GMP standards.